Erythromelalgia is a rare vascular disorder characterized by recurrent episodes of painful erythema and hyperemia of the extremities, most commonly the feet, although the palms may also be affected. These episodes are accompanied by intense pain, burning, and a sensation of heat that occurs in response to temperature changes or physical activity. Symptoms of erythromelalgia can vary greatly in both intensity and duration, making the disorder difficult to diagnose and treat. Erythromelalgia may be a primary condition or a manifestation of various comorbidities, which adds to the complexity of clinical practice.
History of the disease and interesting historical facts
Erythromelalgia was first described in medical literature in the early 20th century. In 1913, English physician T. H. Maxwell published an article on the condition, and since then, the disease has been the subject of active study by doctors. Interesting facts about the disease include its association with various conditions, such as polycythemia vera, as well as genetic mutations in certain genes. Over the centuries, researchers have diagnosed erythromelalgia in various patients, but there are still many unanswered questions about the mechanisms of its occurrence and various therapeutic approaches.
Epidemiology
Erythromelalgia is considered a rare condition and the exact prevalence statistics remain uncertain. Most studies report the occurrence of the disease in the range of 1 to 5 cases per 100,000 people. However, a significant number of cases may go undiagnosed due to the variety of manifestations and possible similarities with other pathologies such as Raynaud's syndrome. It is important to note that men and women are affected by this disease with approximately equal frequency, but the age of onset varies from childhood to old age.
Genetic predisposition
According to modern research, erythromelalgia may have a genetic predisposition, which in most cases is associated with mutations in the SCN9A gene, which codes for sodium channels responsible for the conduction of pain impulses. These mutations lead to hyperactivation of the channel and, as a result, increased sensitivity to pain. Associations with other genes, such as SCN10A and SCN11A, have also been found. About 80% patients with the primary form of erythromelalgia have a mutation in the SCN9A gene, which emphasizes the importance of genetic testing for the diagnosis of this condition.
Risk factors for the development of the disease
Risk factors that contribute to the development of erythromelalgia include:
- Genetic predisposition, especially a family history of the disease.
- Chronic diseases such as polycythemia vera and other vascular pathologies.
- Physical factors: high physical activity or trauma to the limbs.
- Chemical factors: exposure to certain toxic substances or drugs.
- Temperature changes, such as cold or high ambient temperatures, can trigger episodes of flushing.
Diagnosis of this disease
Diagnosis of erythromelalgia includes a comprehensive clinical examination, analysis of symptoms and the results of various laboratory and radiological studies. The main symptoms of the disease are:
- Severe pain and discomfort in the limbs resulting from temperature changes.
- Hyperemia of the skin, accompanied by swelling and a feeling of heat.
- Increased pain with physical activity.
Laboratory tests may include a complete blood count, glucose and electrolyte levels, and specific genetic tests to identify mutations in relevant genes. Radiologic tests, such as vascular ultrasound, may be useful to rule out other vascular disorders. Differential diagnoses include conditions such as Raynaud's syndrome, neuropathies, and microvascular disorders.
Treatment
Treatment of erythromelalgia can be either conservative or surgical, depending on the severity of symptoms and their impact on the patient's quality of life. General therapy may include:
- Lifestyle changes: avoiding triggers such as vigorous physical activity or exposure to high temperatures.
- Pharmacological treatment including nonsteroidal anti-inflammatory drugs and analgesics.
- Surgical procedures such as sympathectomy may be appropriate in cases where drug therapy is unsuccessful.
- Using physical therapy and physiotherapy techniques to improve limb health.
List of medications used to treat this disease
The following medications may be used to treat erythromelalgia:
- Nonsteroidal anti-inflammatory drugs (eg, ibuprofen, naproxen).
- Antidepressants (amitriptyline, duloxetine) for pain relief.
- Anticonvulsants (eg, gabapentin) as an adjunct to primary therapy.
- Narcotic analgesics for the relief of severe pain in severe cases.
Disease monitoring
Monitoring of erythromelalgia involves regular observation of the patient's condition, assessment of symptoms, and analysis of the effectiveness of the treatment. Control stages include:
- Evaluate response to therapy every few months.
- Conducting laboratory tests to exclude concomitant diseases.
- Maintenance therapy and adjustment of the treatment regimen as needed.
The prognosis of the disease in most patients depends on the timeliness of diagnosis and the adequacy of treatment. Although erythromelalgia can significantly reduce the quality of life, remissions and improvements are possible with properly selected therapy. Possible complications may include chronic pain syndrome and the development of concomitant depressive states due to chronic discomfort.
Age-related features of the disease
Erythromelalgia can manifest at any age, but most cases occur in adults aged 30 to 50 years. The disease sometimes occurs in children, but its course may vary. In older people, erythromelalgia is usually associated with concomitant diseases, the frequency of which increases with age, which can complicate diagnosis and choice of treatment tactics.
Questions and Answers
- What causes erythromelalgia? Erythromelalgia can be caused by mutations in genes that affect pain signaling, as well as various underlying medical conditions and environmental factors.
- How is erythromelalgia diagnosed? Diagnosis includes patient questionnaires, clinical observations, laboratory tests and genetic testing.
- What are the main treatments for erythromelalgia? Treatment may include medication, lifestyle changes, and, in rare cases, surgery.
- Is erythromelalgia a chronic condition? Yes, erythromelalgia is chronic and may require long-term therapy and monitoring.
- Can erythromelalgia lead to other diseases? Yes, long-term disease can lead to associated conditions such as depression and chronic pain syndrome.
In my practice, I, Dr. Oleg Korzhikov, often encounter questions from patients about how to cope with the symptoms of erythromelalgia. The main advice is to keep a diary of episodes, recording triggers and possible methods of symptom relief. This will help not only you, but also your doctor to better understand your condition and correlate treatment. It is also extremely important to avoid situations that can provoke an exacerbation, and to approach the choice of therapy taking into account the individual characteristics of the body. Do not forget to actively take care of your health and consult a doctor if new symptoms appear.
